Sonic Healthcare (ASX:SHL) announced its financial performance for the half-year ended Dec. 31, 2025, marked by double-digit revenue growth and a steadfast commitment to its full-year outlook.
The global healthcare provider reported a 17% growth in revenue, reaching $5.45 billion, a result bolstered by a solid 5% organic growth rate and the successful integration of recent acquisitions.
EBITDA rose 10% to $907 million, while net profit grew 11% to reach $262 million.
The performance translated to earnings per share of 53.1 cents, representing an 8% increase over the previous period.
Management attributed these gains to effective operating leverage, synergy realisation, and a disciplined approach to cost control across its international operations.
CEO Dr. Jim Newcombe highlighted the "strength and global diversity" of the group, noting that the company remains on track to meet its full-year EBITDA guidance of $1.87 to $1.95 billion.
The company hiked its interim dividend to 45 cents per share.
Sonic is conducting an operational review of its US business to further rationalise its anatomical pathology operations and enhance long-term margins.